GlucoTrack Inc. Common Stock (GCTK)
Stock · NASDAQ · Health Care
$0.725as of 10/16/2026
Price chart
Active signals
GCTK Signal Track Record
How signals performed across all stocks →What GCTK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 27 | -11.0% | 30% | June 10, 2026 |
| Volume Spike | 17 | -25.3% | 29% | September 23, 2026 |
| Bollinger Band Breakout | 16 | -28.8% | 25% | August 31, 2026 |
| Any 20-session window (baseline) | -12.4% | 23% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GCTK
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed it…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 15
- Website
- glucotrack.com/
Fundamentals
- 1-day range
- $1.59$1.82
- Market cap
- $4.25M
- P/E (trailing)
- 0.07
- P/E (forward)
- —
- EPS (trailing)
- $-115.36
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 2.07M
How GlucoTrack Inc. Common Stock Makes Money
Where the revenue actually goes — FY2019 annual results
Source: 10-K filed Apr 14, 2020 · via SEC EDGAR / Finnhub
GlucoTrack Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GCTKGlucoTrack Inc. Common Stock$0.725▼ 12.86%Market cap $4.25MP/E 0.07$1.77$136.29
- VVOSVivos Therapeutics Inc. Common Stock$0.131▼ 8.39%Market cap $4.47MP/E —$0.1276$3.28
- INBSIntelligent Bio Solutions Inc. Common Stock$1.5▲ 4.17%Market cap $4.76MP/E —$1.35$24.9
- XAIRBeyond Air Inc. Common Stock$2.16▼ 2.26%Market cap $4.93MP/E —$2.31$55.6
- NXGLNexGel Inc Common Stock$5.59▲ 7.92%Market cap $3.13MP/E —$3$57
- SNOASonoma Pharmaceuticals Inc. Common Stock$1.12▼ 2.61%Market cap $5.99MP/E —$0.8501$4.25
- IVFINVO Fertility Inc. Common Stock$0.558▼ 5.58%Market cap $2.39MP/E —$0.58$84.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GCTK GlucoTrack Inc. Common Stock | $4.25M | 0.07 | $0.725 | ▼ 12.86% | $1.77$136.29 |
| VVOS Vivos Therapeutics Inc. Common Stock | $4.47M | — | $0.131 | ▼ 8.39% | $0.1276$3.28 |
| INBS Intelligent Bio Solutions Inc. Common Stock | $4.76M | — | $1.5 | ▲ 4.17% | $1.35$24.9 |
| XAIR Beyond Air Inc. Common Stock | $4.93M | — | $2.16 | ▼ 2.26% | $2.31$55.6 |
| NXGL NexGel Inc Common Stock | $3.13M | — | $5.59 | ▲ 7.92% | $3$57 |
| SNOA Sonoma Pharmaceuticals Inc. Common Stock | $5.99M | — | $1.12 | ▼ 2.61% | $0.8501$4.25 |
| IVF INVO Fertility Inc. Common Stock | $2.39M | — | $0.558 | ▼ 5.58% | $0.58$84.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 155.2K
- Total value held
- $74.5K
- Institutional holders
- 12
- Unknown47.0K
- Unknown45.8K
- Unknown40.6K
- Unknown13.5K
- Unknown4.0K
- Unknown3.4K
- Unknown702
- Unknown34
- Unknown9
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GCTK’s Lōkahi Expands Collaboration & Launches Qare
Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.
GCTK’s Lōkahi Expands Collaboration & Launches Qare. Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.